

*Annual Review of Cancer Biology*  
**The Multifaceted Role of  
 Regulatory T Cells in  
 Breast Cancer**

Kevin Kos<sup>1</sup> and Karin E. de Visser<sup>1,2</sup>

<sup>1</sup>Division of Tumor Biology and Immunology, Oncode Institute, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands; email: k.d.visser@nki.nl

<sup>2</sup>Department of Immunology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands

Annu. Rev. Cancer Biol. 2021. 5:291–310

First published as a Review in Advance on  
 December 4, 2020

The *Annual Review of Cancer Biology* is online at  
[cancerbio.annualreviews.org](http://cancerbio.annualreviews.org)

<https://doi.org/10.1146/annurev-cancerbio-042920-104912>

Copyright © 2021 by Annual Reviews.  
 This work is licensed under a Creative Commons  
 Attribution 4.0 International License, which  
 permits unrestricted use, distribution, and  
 reproduction in any medium, provided the original  
 author and source are credited. See credit lines of  
 images or other third-party material in this article  
 for license information

**ANNUAL  
 REVIEWS CONNECT**

[www.annualreviews.org](http://www.annualreviews.org)

- Download figures
- Navigate cited references
- Keyword search
- Explore related articles
- Share via email or social media

**Keywords**

regulatory T cell, breast cancer, metastasis, tumor microenvironment, immunosuppression

**Abstract**

The microenvironment of breast cancer hosts a dynamic cross talk between diverse players of the immune system. While cytotoxic immune cells are equipped to control tumor growth and metastasis, tumor-corrupted immunosuppressive immune cells strive to impair effective immunity and promote tumor progression. Of these, regulatory T cells (T<sub>regs</sub>), the gatekeepers of immune homeostasis, emerge as multifaceted players involved in breast cancer. Intriguingly, clinical observations suggest that blood and intratumoral T<sub>regs</sub> can have strong prognostic value, dictated by breast cancer subtype. Accordingly, emerging preclinical evidence shows that T<sub>regs</sub> occupy a central role in breast cancer initiation and progression and provide critical support to metastasis formation. Here, T<sub>regs</sub> are not only important for immune escape but also promote tumor progression independent of their immune regulatory capacity. Combining insights into T<sub>reg</sub> biology with advances made across the rapidly growing field of immuno-oncology is expected to set the stage for the design of more effective immunotherapy strategies.

## 1. THE IMMUNE SYSTEM: A DOUBLE-EDGED SWORD IN CANCER

Tumors are complex entities consisting of not just cancer cells but also a variety of nonmalignant cell types. The local niche within and surrounding tumors is collectively described as the tumor microenvironment (TME), which can profoundly impact the development and progression of cancer (Blomberg et al. 2018, Garner & de Visser 2020, Hanahan & Weinberg 2011). It is now clear that the TME is not a static element of tumors, but its composition and functional state are highly diverse between cancer types, subtypes, and even individual tumors. In the past several decades, the immunological component of the TME has been studied extensively, with a focus on answering the central question: How can tumors develop in the context of a functional immune system? Addressing this fundamental question is essential to fully exploit the immune system for the treatment of cancer.

Breast cancer is perhaps one of the most studied cancer types in the context of the TME. Although survival rates for breast cancer patients are steadily increasing, it is still the leading cause of cancer-related deaths in women worldwide (Bray et al. 2018, DeSantis et al. 2019). The vast majority of breast cancer-related mortality is due to the incurable metastatic stage of the disease. Clearly, understanding, preventing, and treating metastatic breast cancer are unmet needs. As such, mechanistic insights into the complex interactions of key players in the TME could pave the way for novel innovative treatments and improved patient stratification.

Clinical studies have exposed a dual role of the immune system in breast cancer. For example, tumor-associated macrophages (TAMs) are associated with invasion, metastasis, and a worse prognosis (Qiu et al. 2018), while tumor-infiltrating lymphocytes (TILs) are associated with a favorable prognosis (Denkert et al. 2018). To understand this duality, one must realize that cancers host a plethora of immune cell subsets, such as lymphocytes, various myeloid cells, and innate lymphoid cells, to which both pro- and antitumorigenic functions have been attributed (Blomberg et al. 2018). Although immune cells such as CD8<sup>+</sup> T cells and natural killer (NK) cells have the molecular gear to recognize and eradicate malignant cells, they often encounter a highly immunosuppressive environment in tumors, which blunts effective antitumor immunity. This milieu is characterized by widespread expression of immune checkpoint receptors, inhibitory cytokines, hypoxia, and low levels of nutrients, all of which restrain the recruitment and function of cytotoxic immune cells (Binnewies et al. 2018). Importantly, lymphocytes and tumor-associated myeloid cells including macrophages, neutrophils, and monocytes profoundly contribute to the creation of this immunosuppressive environment, as well as to the systemic immunosuppression that often accompanies primary tumor growth and further potentiates cancer progression by facilitating immune escape (Garner & de Visser 2020).

A key orchestrator of immunosuppression is the CD4<sup>+</sup> regulatory T cell (T<sub>reg</sub>), which since its discovery has been in the crosshairs of cancer immunology research (Plitas & Rudensky 2020, Yano et al. 2019). T<sub>regs</sub> can be abundantly present in primary breast tumors and metastases (Syed Khaja et al. 2017). Still, their exact impact and relevance to breast cancer progression have proven challenging to uncover due to the complexities of immune cell cross-talk and metastatic disease. Recently, fundamental and preclinical research has provided exciting new insights into the biology of T<sub>regs</sub> in breast cancer. This comes at an important time, as initial results for immune checkpoint inhibitors in breast cancer have been relatively disappointing (Planes-Laine et al. 2019). The expanding use of these drugs for the treatment of breast cancer therefore necessitates a comprehensive understanding of immunosuppressive T<sub>regs</sub>: Are we pulling the right strings? In this review, we therefore explore and discuss the current knowledge, challenges, and clinical use of T<sub>regs</sub> in breast cancer.

## 2. T<sub>REGS</sub>: GATEKEEPERS OF IMMUNE HOMEOSTASIS

### 2.1. The Discovery and Biology of T<sub>regs</sub>

The immune system is a sophisticated defense network, evolved to withstand innumerable pathogenic challenges at any anatomical location. To do so, complex cellular interactions coordinate pathogen recognition, immune cell activation, and the execution of effector programs. In order to return to or maintain homeostasis, immunosuppressive signals are essential to dampen immune responses to prevent pathological immune responses such as chronic inflammation or autoimmunity. A key cell type involved in this process is the T<sub>reg</sub>. The importance of T<sub>regs</sub> in immune tolerance has become evident through characterization of so-called scurfy mice, which suffer from a severe lethal autoimmune syndrome characterized by inflamed skin, red eyes, enlarged lymphoid organs, and early death (Russell et al. 1959). Scurfy mice were first reported in 1949, but it was not until the early 2000s that a mutation in the *Foxp3* gene, and consequential loss of T<sub>regs</sub>, was identified as a direct cause for the severe immune pathology (Brunkow et al. 2001). Further research showed that FOXP3 is the master transcription factor (TF) for the previously identified specialized immunosuppressive CD4<sup>+</sup> CD25<sup>+</sup> T lymphocytes, now known as T<sub>regs</sub> (Fontenot et al. 2003, Hori et al. 2003). Since then, it has become clear that reduced T<sub>reg</sub> numbers or impaired T<sub>reg</sub> functionality stands at the basis of autoimmune and inflammatory diseases such as diabetes, multiple sclerosis, and inflammatory bowel disease (Bluestone et al. 2015, Leonard et al. 2017). In contrast, their activation and accumulation in tumors are considered detrimental, as we explore below in depth.

T<sub>regs</sub> utilize several strategies to antagonize both adaptive and innate immunity. Among these, the release of immunosuppressive mediators, such as IL-10, TGF- $\beta$ , and adenosine, and high expression of immunomodulatory receptors, such as CTLA-4, PD-L1, and LAG-3, are well established aspects of T<sub>reg</sub> functionality that can interfere with the propagation of immune responses (Josefowicz et al. 2012a, Lucca & Dominguez-Villar 2020, Yano et al. 2019). Scavenging of IL-2 from the environment and killing of effector T cells by the release of granzymes additionally contribute to immunosuppression (Loebbermann et al. 2012, Vignali et al. 2008). Combined, these mechanisms can be employed to restrain dendritic cell (DC) function or directly inhibit cytotoxic cells (Vignali et al. 2008). The exact effector program that is engaged is highly dependent on the tissue and nature of the immune response (Josefowicz et al. 2012a, Koizumi & Ishikawa 2019). Emerging evidence shows that T<sub>regs</sub> can acquire expression of T helper (T<sub>h</sub>) subset TFs, such as T-bet, GATA3, and ROR $\gamma$ T, which direct their function towards suppression of T<sub>h</sub> cells of that particular subset (Josefowicz et al. 2012a, Koizumi & Ishikawa 2019). For example, T<sub>regs</sub> expressing the T helper type 1 (T<sub>h</sub>1) TF T-bet are important for suppressing T<sub>h</sub>1-mediated inflammation but cannot suppress T<sub>h</sub>2 or T<sub>h</sub>17 responses (Chinen et al. 2016).

### 2.2. Two Flavors of FOXP3<sup>+</sup> T<sub>regs</sub>

In vivo, two distinct populations of FOXP3<sup>+</sup> T<sub>regs</sub> are defined, based on their ontogeny and stability: thymically developed (natural) T<sub>regs</sub> and extrathymically developed (peripheral or induced) T<sub>regs</sub>. Thymic T<sub>regs</sub> (tT<sub>regs</sub>) represent a dedicated lineage with stable expression of FOXP3 and affinity for self-antigen. The generation of tT<sub>regs</sub> occurs through a unique developmental program in the thymus, based on a delicate balance of T cell receptor (TCR) affinity and antigen specificity of CD4<sup>+</sup> progenitor cells (Legoux et al. 2015, Malhotra et al. 2016, Moran et al. 2011). Through this program, tT<sub>regs</sub> are equipped with TCRs biased towards recognition of tissue-restricted self-antigens, which enable the suppression of immune responses directed towards host peptides upon activation via their TCRs (Jordan et al. 2001, Kieback et al. 2016, Sakaguchi et al. 2008).

Unlike  $tT_{\text{regs}}$ , peripheral  $T_{\text{regs}}$  ( $pT_{\text{regs}}$ ) are extrathymically generated in the periphery from nonregulatory  $FOXP3^- CD4^+$  T cells. A crucial element of  $pT_{\text{reg}}$  differentiation is their dependence on TGF- $\beta$  signaling, which in  $FOXP3^- CD4^+$  T cells induces the interaction of SMAD2/3 with an intronic enhancer in the *FOXP3* locus, CNS1 (Kanamori et al. 2016, Marie et al. 2005, Zheng et al. 2010).  $pT_{\text{regs}}$  have unstable *FOXP3* expression and lack the characteristic demethylation of the intronic element CNS2 observed in  $tT_{\text{regs}}$ , which is essential for  $T_{\text{reg}}$  stability during proliferation (Kanamori et al. 2016, Lee & Lee 2018). In addition,  $pT_{\text{regs}}$  display a TCR repertoire that recognizes foreign antigens, parallel to conventional  $CD4^+$  T cells (Curotto de Lafaille & Lafaille 2009). As such,  $pT_{\text{regs}}$  have been found to play important roles at barrier sites, including the gut, lungs, and placenta, to mitigate inflammatory responses in response to foreign, but harmless, environmental, dietary, and microbial antigens (Esterházy et al. 2019, Josefowicz et al. 2012b, Kalekar et al. 2016, Soroosh et al. 2013).

The specific contributions of either  $tT_{\text{regs}}$  or  $pT_{\text{regs}}$  in cancer remain elusive, as to date no genuine phenotypic or functional marker has been discovered to distinguish both  $T_{\text{reg}}$  subtypes in vivo (Szurek et al. 2015). Instead, the ontogeny of  $T_{\text{regs}}$  in human cancer samples can be assessed ex vivo either via TCR repertoire sequencing or via epigenetic analysis of the CNS2 element in the *FOXP3* gene, which is demethylated in  $tT_{\text{regs}}$  but mostly methylated in  $pT_{\text{regs}}$ . As most studies on  $T_{\text{regs}}$  do not distinguish between  $tT_{\text{regs}}$  and  $pT_{\text{regs}}$ , below we refer to these cells as  $T_{\text{regs}}$ , unless stated otherwise.

Now, nearly two decades after their discovery, the extent of  $T_{\text{reg}}$  functionality appears astonishingly diverse.  $T_{\text{regs}}$  play critical roles in tissue regeneration and repair, intestinal regulation of the microbiome, hair morphogenesis, metabolic homeostasis, pregnancy, and cancer (Josefowicz et al. 2012a, Sharma & Rudra 2018). However, it is less clear which mechanisms are engaged in the context of breast cancer progression and metastasis. Therefore, below we first review the evidence for the clinical relevance of  $T_{\text{regs}}$  in breast cancer.

### 3. CLINICAL SIGNIFICANCE OF $T_{\text{REGS}}$ IN BREAST CANCER

#### 3.1. Prognostic Value of $T_{\text{regs}}$ in Breast Cancer

The discovery in 2001 that  $CD4^+ CD25^+$  immunosuppressive cells can be found in the blood of healthy individuals (Baecher-Allan et al. 2001) kick-started research into the presence and behavior of these cells in cancer patients. In the following years, it was reported that  $CD4^+ CD25^+$  T cells are increased in blood and tumors of patients with a variety of cancers, including breast, pancreatic, ovarian, and non-small-cell lung cancer (NSCLC) (Mougiakakos et al. 2010). However, as  $CD25$  expression is not restricted to  $T_{\text{regs}}$ , but can also be expressed by effector T cells, it was not until the discovery of *FOXP3* as a unique marker of  $T_{\text{regs}}$  (Fontenot et al. 2003, Hori et al. 2003) and the development of reliable monoclonal antibodies that the presence of  $T_{\text{regs}}$  could be convincingly demonstrated in human cancers (Bates et al. 2006, Roncador et al. 2005). Since then, many studies have investigated the association between the presence of intratumoral  $T_{\text{regs}}$  and patient survival and therapy response in breast cancer (Table 1).

Despite an extensive body of literature, the clinical significance of  $T_{\text{regs}}$  in breast cancer remains controversial due to conflicting results among studies (Table 1). A key challenge in interpreting these studies is that the prognostic value of  $T_{\text{regs}}$  seems to differ by molecular breast cancer subtype. These subtypes are broadly defined on the basis of tumoral expression of the estrogen and progesterone hormone receptors ( $HR^+$ ) and the growth factor receptor HER2 or the absence of these [triple-negative breast cancer (TNBC)] (DeSantis et al. 2019). Several meta-analyses published over the last few years have showed that high *FOXP3* TILs in  $HR^+$  breast tumors correlate with poor survival, high grade, and lymph node involvement (Jiang et al. 2015, Wang et al. 2016,

**Table 1** Prognostic significance of FOXP3 TILs across breast cancer subtypes

Subtype analyzed	Patients ( <i>n</i> )	Correlations with high FOXP3 TILs:			Reference
		Prognosis	Subtype	Clinical features	
DCIS	62	Poor (univariate)	DCIS <sup>d</sup>	ND	Bates et al. 2006
ER <sup>-</sup>	77	No effect	ER <sup>-</sup>	High grade, LN met <sup>+</sup>	
ER <sup>+</sup>	148	Poor (univariate)			
ER <sup>-</sup>	364	No effect	ER <sup>-</sup> ; HER2 <sup>+</sup> ; basal	High grade, LN met <sup>+</sup> , large tumor size	Mahmoud et al. 2011
ER <sup>+</sup>	982	Poor (univariate) <sup>a</sup>			
Mixed	398	Poor (multivariate)	ER <sup>-</sup> ; HER2 <sup>+</sup> ; basal	High grade	Yan et al. 2011
Mixed	1,270	Poor (multivariate)	ER <sup>-</sup> ; PR <sup>-</sup> ; HER2 <sup>+</sup>	High grade	Liu et al. 2011
Mixed	72	Poor (univariate) <sup>a</sup>	NS	LN met <sup>+</sup> , p53 <sup>+</sup> , Ki67 <sup>+</sup>	Kim et al. 2013
Mixed	90	Poor (multivariate)	ER <sup>-</sup> ; HER2 <sup>+</sup>	High grade	Takenaka et al. 2013
Mixed	90	Poor (univariate) <sup>a</sup>	HER2 <sup>+</sup>	High grade, LN met <sup>+</sup> , large tumor size	Maeda et al. 2014
Mixed	498	Poor (univariate) <sup>a</sup>	HER2 <sup>+</sup> ; TNBC	High $\gamma\delta$ T cell	Allaoui et al. 2017
Mixed	118	Poor (univariate)	ND	High grade, LN met <sup>+</sup> , Ki67 <sup>+</sup> , tumor nest	Peng et al. 2019
TNBC	86	Favorable (multivariate)	ND	LN met <sup>+</sup>	Lee et al. 2013
ER <sup>-</sup> HER2 <sup>-</sup>	175	Favorable (univariate)	NS	High grade, high CD8 <sup>+</sup> , young age	West et al. 2013
ER <sup>-</sup> HER2 <sup>+</sup>		No effect			
ER <sup>+</sup>	2,166	No effect (multivariate) <sup>b</sup>	ER <sup>-</sup> ; HER2 <sup>+</sup> ; basal	High grade, LN met <sup>+</sup> , High CD8 <sup>+</sup> , young age	Liu et al. 2014
ER <sup>-</sup> HER2 <sup>+</sup>	250	No effect (multivariate) <sup>c</sup>			
Basal	330	Favorable (multivariate)	ER <sup>+</sup>	ND	Tsang et al. 2014
ER <sup>+</sup>	554	ND			
ER <sup>-</sup> HER2 <sup>+</sup>	218	No effect	ND	High grade, high CD8 <sup>+</sup> , high PD1 <sup>+</sup>	Sun et al. 2014
Mixed					
TNBC	101	No effect	ND	High CD8 <sup>+</sup>	Miyashita et al. 2015
Mixed	207	No effect	ER <sup>-</sup> ; HER2 <sup>+</sup> ; TNBC	High grade, Ki67 <sup>+</sup>	Papaioannou et al. 2019

Abbreviations: DCIS, ductal carcinoma in situ; ER, estrogen receptor; LN met<sup>+</sup>, lymph node involvement; ND, not determined; NS, no significant differences; PR, progesterone receptor; TIL, tumor-infiltrating lymphocytes; TNBC, triple-negative breast cancer.

<sup>a</sup>Not significant in multivariate analysis.

<sup>b</sup>Poor prognosis in low-CD8<sup>+</sup> tumors.

<sup>c</sup>Favorable prognosis in high-CD8<sup>+</sup> tumors.

<sup>d</sup>Compared to normal breast.

Zhou et al. 2017). However, multivariate Cox regression on patient outcomes, including adjustments for tumor size, grade, and lymph node stage, has revealed that FOXP3 TILs are not an independent prognostic factor in HR<sup>+</sup> breast tumors (Liu et al. 2014, Mahmoud et al. 2011). Whether T<sub>regs</sub> are causally involved in the differentiation of high-grade tumors, lymph node metastasis, and poor prognosis cannot be determined from these descriptive analyses. In contrast to HR<sup>+</sup> breast cancer, FOXP3 TILs strongly correlate with a favorable prognosis in HR<sup>-</sup> and TNBC subtypes (Jiang et al. 2015, Mahmoud et al. 2011, Tsang et al. 2014, West et al. 2013). Here, T<sub>reg</sub> infiltration is strongly associated with high CD8<sup>+</sup> and T<sub>h</sub> cell infiltration, perhaps reflecting a

T cell-permissive environment (Seo et al. 2013). This is further supported by the observation that  $T_{\text{regs}}$  are not associated with prognosis in triple-negative tumors with low  $CD8^+$  T cell infiltration (West et al. 2013). In conclusion,  $T_{\text{regs}}$  correlate with disease outcomes in a subtype-dependent manner, but future preclinical research is needed to uncover the mechanistic link between  $T_{\text{regs}}$  and breast cancer subtypes.

### 3.2. Predictive Value of $T_{\text{regs}}$ in Cancer Immunotherapy

Novel therapeutics targeting immune checkpoints such as PD-1/PD-L1 and CTLA-4 are transforming the treatment landscape across cancer types (Wei et al. 2018). In order to maximize efficacy, numerous studies are currently evaluating predictive biomarkers and novel treatment combinations (Kim et al. 2019). Importantly,  $T_{\text{regs}}$  can be direct targets of these treatments due to their high expression of immune checkpoint molecules (Togashi et al. 2019). While the use of immunotherapy in breast cancer is still in its infancy, research in other cancer types has revealed the potential predictive significance of  $T_{\text{regs}}$  in the context of PD-1/PD-L1 blockade. For example, PD-1 blockade has been associated with disease progression in gastric cancer (GC) patients via the activation and expansion of intratumoral PD-1<sup>+</sup>  $T_{\text{regs}}$  (Kamada et al. 2019). Accordingly, PD-1 expression by intratumoral  $T_{\text{regs}}$  was found to predict resistance to anti-PD-1 therapy in multiple NSCLC and GC patient cohorts (Kumagai et al. 2020). In addition, high intratumoral  $T_{\text{reg}}$  proliferation in response to anti-PD-1 therapy has been linked to recurrence (Huang et al. 2019). Finally, PD-L1-mediated expansion of p $T_{\text{regs}}$  is an important immunosuppressive axis in glioblastoma (DiDomenico et al. 2018). In recent years, the first trials investigating the efficacy of immune checkpoint blockade (ICB) in metastatic TNBC have been published, with a strong focus on PD-1/PD-L1 blockade (Adams et al. 2019, Dirix et al. 2018, Emens et al. 2019, Nanda et al. 2016, Planes-Laine et al. 2019, Schmid et al. 2018, Voorwerk et al. 2019). Although clinical benefit is observed for a small proportion (approximately 5–20%) of breast cancer patients, emerging evidence shows that selecting patients based on immune parameters such as a high TIL score and high PD-L1 expression may modestly improve response rates (Emens et al. 2019). Up until now,  $T_{\text{regs}}$  have not been specifically reported to be correlated with efficacy in these early studies. As such, research in the coming years should clarify whether  $T_{\text{regs}}$  are predictive for the success of PD-1/PD-L1-based treatments in breast cancer.

### 3.3. Qualitative Clinical Assessment of $T_{\text{regs}}$ in Breast Cancer

Besides quantification of intratumoral  $T_{\text{regs}}$ , there is a growing body of evidence indicating that a more in-depth qualitative assessment of  $T_{\text{regs}}$ , including information on phenotype, functional state, and immune cell cross talk, may be important for disease outcome. For example, recent reports have shown that intratumoral  $T_{\text{regs}}$  from breast cancer patients display an activated phenotype with high expression of CD25, CTLA-4, and PD-1 and exert immunosuppressive activity (Gobert et al. 2009, Plitas et al. 2016, Syed Khaja et al. 2017). In one of these studies, the transcriptome of  $T_{\text{regs}}$  from 105 treatment-naïve breast cancer patients was analyzed (Plitas et al. 2016). The chemokine receptor CCR8 was identified to be uniquely expressed by intratumoral  $T_{\text{regs}}$ , but not by  $T_{\text{regs}}$  isolated from breast tissue and blood from healthy donors. CCR8<sup>+</sup>  $T_{\text{regs}}$  were found to be highly proliferative and enriched in high-grade tumors. Strikingly, while intratumoral  $T_{\text{reg}}$  abundance based on *FOXP3* mRNA expression did not correlate with clinical features, stratifying patients based on the *CCR8:FOXP3* ratio in the tumor revealed a strong correlation with poor survival in patients (Plitas et al. 2016). These findings illustrate that in-depth analysis of intratumoral  $T_{\text{regs}}$  provides important information. As the patients in this cohort predominantly had

HR<sup>+</sup> tumors (74.3%), an important next step would be to validate these findings in HER2<sup>+</sup> and TNBC subtypes, in which T<sub>regs</sub> are associated with good prognosis (West et al. 2013).

Many studies have reported increased frequencies of T<sub>regs</sub> in the peripheral blood of breast cancer patients across subtypes (Decker et al. 2012, Horlock et al. 2009, Liyanage et al. 2002, Perez et al. 2007, Wolf et al. 2003), indicating that breast tumors can systemically engage T<sub>regs</sub>. Still, their significance remained elusive for a long time until a recent in-depth analysis performed on T<sub>regs</sub> isolated from the blood and tumors of breast cancer patients (Wang et al. 2019). It was found that a subpopulation of T<sub>regs</sub> (FOXP3<sup>hi</sup> CD45RA<sup>neg</sup>) (Miyara et al. 2009), comprising approximately 19% of the total T<sub>reg</sub> population in the peripheral blood of patients, strongly resembles intratumoral T<sub>regs</sub>, based on phenotype, TCR repertoire, and CCR8 expression. This may suggest that intratumoral T<sub>regs</sub> derive from FOXP3<sup>hi</sup> CD45RA<sup>neg</sup> T<sub>regs</sub> in peripheral blood, or vice versa. These T<sub>regs</sub> from blood had superior suppressive potential in vitro, compared to FOXP3<sup>low</sup> CD45RA<sup>pos/neg</sup> T<sub>regs</sub>. FOXP3<sup>hi</sup> CD45RA<sup>neg</sup> T<sub>regs</sub> were found to be heterogeneous between patients in their signaling response to both immunosuppressive and inflammatory cytokines. High-T<sub>reg</sub> responsiveness to immunosuppressive cytokines correlated with poor survival, whereas high responsiveness to inflammatory cytokines had the opposite effect (Wang et al. 2019). This exposes the potential clinical significance of T<sub>regs</sub> in the peripheral blood of breast cancer patients, but also highlights how T<sub>reg</sub> heterogeneity may potentially influence disease outcomes.

Over recent years, studies focusing on FOXP3 TILs have been moving from basic quantification analyses towards sophisticated in-depth characterization, yielding exciting new insights with prognostic and potential therapeutic implications. As we are starting to discover the characteristics of T<sub>regs</sub> with tumor-promoting capabilities, mechanistic studies should investigate their functional roles in breast cancer progression, and whether their emergence can be therapeutically halted.

## 4. MECHANISTIC UNDERSTANDING OF T<sub>REGS</sub> IN BREAST CANCER

### 4.1. The Context-Dependent Functional Role of T<sub>regs</sub> in Breast Cancer Progression

Preclinical animal models are key to mechanistically understanding how T<sub>regs</sub> impact breast cancer progression. An important tool to dissect T<sub>reg</sub> function in these models is their systemic depletion, which can be achieved via two strategies. Firstly, antibody-based approaches deplete T<sub>regs</sub> through targeting of cell-surface receptors that are highly expressed on T<sub>regs</sub>, including CD25, GITR, and FR4 (Arce Vargas et al. 2017, Coe et al. 2010, Yamaguchi et al. 2007). Secondly, the development of transgenic mice that express the diphtheria toxin receptor (DTR) under control of *Foxp3* either via direct knockin (*Foxp3*<sup>DTR</sup> mice) or by its introduction using a bacterial artificial chromosome [DEREG (depletion of T<sub>regs</sub>) mice] has allowed for short-term inducible depletion of T<sub>regs</sub> upon injection of diphtheria toxin (DT) (Kim et al. 2007, Lahl et al. 2007). A transgenic mouse model for mammary tumorigenesis that is regularly used to study the biology of T<sub>regs</sub> in breast cancer is the MMTV-PyMT (mouse mammary tumor virus–polyoma middle tumor-antigen) mouse model. T<sub>regs</sub> have been shown to highly infiltrate mammary tumors of MMTV-PyMT mice, depending in part on CCR2 expression on T<sub>regs</sub> (Loyher et al. 2016). Ablation of T<sub>regs</sub> in *Foxp3*<sup>DTR</sup> mice with orthotopically transplanted MMTV-PyMT tumors drastically reduced tumor growth and pulmonary metastases (Bos et al. 2013). Mechanistically, IFN $\gamma$  and CD4<sup>+</sup> conventional T cells were required for the observed antitumor effect, which was independent of CD8<sup>+</sup> T cells and NK cells. As proinflammatory signaling by myeloid cells was increased upon T<sub>reg</sub> depletion, the authors of this study speculated that IFN $\gamma$ -activated macrophages may contribute to antitumoral inflammation (Bos et al. 2013).


The observation that  $T_{\text{regs}}$  constrain antitumor immunity in tumors has been reported by others. For example, anti-CD25 treatment in mice inoculated with 4T1 cancer cells strongly reduced tumor growth, which correlated with an increase in DCs and effector CD8<sup>+</sup> T cells in tumor-draining lymph nodes (TDLNs), suggesting that  $T_{\text{regs}}$  modulate DC function (Goudin et al. 2016). Indeed, it has been reported that  $T_{\text{regs}}$  can inhibit the expression of costimulatory ligands on DCs, thereby restraining CD8<sup>+</sup> T cell activation and tumor clearance in a *Kras*-mutant model for pancreatic cancer (Jang et al. 2017). It would be of interest to investigate whether similar mechanisms are at play in breast cancer. Elimination of  $T_{\text{regs}}$  is not always sufficient to drive strong antitumor responses. For example, immunosuppressive  $T_{\text{regs}}$  were found to be highly enriched in inoculated TNBC T-11 tumors, but DT-based  $T_{\text{reg}}$  ablation only slightly slowed tumor growth.  $T_{\text{reg}}$  ablation did potentiate PD-1/CTLA-4-based immunotherapy, which correlated with an increase in IFN $\gamma$ <sup>+</sup> CD8<sup>+</sup> T cells (Taylor et al. 2017). These findings suggest that  $T_{\text{regs}}$  can form an important barrier for immunotherapy-induced antitumor immunity, which has been reported before in preclinical inoculated melanoma and colon carcinoma tumors (Arce Vargas et al. 2017).

The studies above suggest that targeting  $T_{\text{regs}}$  in (breast) cancer models induces antitumoral inflammation that, sometimes in combination with immunotherapy, may unleash antitumor immune responses. However, therapeutic elimination of  $T_{\text{regs}}$  may trigger autoimmunity in cancer patients, particularly in combination with ICB. Thus, an important next step would be to define the context-dependent molecular mechanisms engaged by  $T_{\text{regs}}$  to enable precise targeting of relevant effector programs instead. A key challenge here is the apparent variability of the clinical significance of  $T_{\text{regs}}$  with breast cancer subtype, which necessitates studying these cells in clinically relevant mouse tumor models. Currently, the vast majority of murine breast cancer cell lines used for inoculation into mice and genetically engineered mouse models (GEMMs) for breast cancer give rise to estrogen receptor–negative (ER<sup>−</sup>) mammary tumors (Özdemir et al. 2018), whereas ~75% of human invasive breast cancers are ER<sup>+</sup> (Bentzen et al. 2007). As  $T_{\text{regs}}$  have been particularly associated with a detrimental role in HR<sup>+</sup> breast cancers, future research should ideally focus on the development and use of HR<sup>+</sup> breast tumor models to uncover the subtype-dependent role of  $T_{\text{regs}}$  in breast cancer.

While  $T_{\text{regs}}$  can interfere with antitumor immunity in the context of established tumors (**Figure 1**), recent findings in spontaneously developing tumor models suggest that at the onset of neoplastic progression,  $T_{\text{regs}}$  may unexpectedly constrain protumoral inflammation. One study reported that DT-based ablation of  $T_{\text{regs}}$  during the early, noninvasive neoplastic phase in the MMTV-PyMT model accelerated the progression of noninvasive lesions into invasive tumors (Martinez et al. 2019). The elimination of  $T_{\text{regs}}$  resulted in the accumulation of macrophages in mammary glands and an induction of the Th2 cytokines IL-4 and IL-5, which have been reported to induce tumorigenic functions in macrophages (DeNardo et al. 2009). The CD44<sup>+</sup> CD24<sup>−</sup> mammary stem cell compartment was also found to be expanded, with increased colony forming capacity in vitro. Whether  $T_{\text{regs}}$  control mammary stem cell proliferation directly, or indirectly via the TME, remains to be addressed. In line with these findings,  $T_{\text{regs}}$  have also been reported to inhibit pancreatic carcinogenesis of neoplastic lesions in a *Kras*-mutant GEMM by repressing the recruitment of immunosuppressive myeloid cells (Zhang et al. 2020). These findings reinforce that  $T_{\text{regs}}$  are potent suppressors of inflammation in early stages of tumorigenesis, which has context-dependent effects on tumor progression. As  $T_{\text{regs}}$  have been found to expand in ductal carcinoma in situ (Bates et al. 2006), more research is needed to uncover whether these cells play a protective or detrimental role in precancerous breast cancer lesions.

Research on  $T_{\text{regs}}$  in other cancer types has revealed the versatile nature of these cells and has uncovered novel mechanisms of immune cell cross talk (Jang et al. 2017). For example,  $T_{\text{reg}}$ -derived IL-10 and IL-35 can promote CD8<sup>+</sup> T cell exhaustion in melanoma (Sawant et al.





**Figure 1**

$T_{\text{regs}}$  modulate their local environment to promote breast cancer progression. Tumor-derived factors such as chemokines, cytokines, and other mediators promote the accumulation and expansion of  $T_{\text{regs}}$  in primary breast tumors and metastatic niches. In the TME,  $T_{\text{regs}}$  constrain both innate and adaptive immune responses to counteract antitumor immunity. Mechanistically,  $T_{\text{regs}}$  can (among other effects) suppress the expression of costimulatory ligands on DCs, release inhibitory modulators that interfere with T cell activation, and are also equipped to induce apoptosis in effector cells (left). However, the effector mechanisms that are engaged in the context of the breast TME remain largely unknown. In addition,  $T_{\text{regs}}$  can enhance metastatic progression of cancer cells in tumor-draining lymph nodes (middle) and lungs (right) through tissue-specific mechanisms. These mechanisms include promoting tumor cell survival and migration via secretion of TGF- $\beta$ , AREG, and RANK-L, as well as inhibiting cytotoxic effector cells. Abbreviations:  $B_{\text{reg}}$ , regulatory B cell; costim., costimulation; DC, dendritic cell; Gal-1, galectin 1; Grzm B, granzyme B; iNOS, inducible nitric oxide synthase;  $M\phi$ , macrophage; NK, natural killer;  $pT_{\text{reg}}$ , peripheral  $T_{\text{reg}}$ ; TME, tumor microenvironment;  $T_{\text{reg}}$ , regulatory T cell.

2019). It is also becoming increasingly clear that  $T_{\text{regs}}$  can interact with a variety of myeloid cells to hamper antitumor immunity, including eosinophils, mast cells, macrophages, neutrophils, and basophils (Blatner et al. 2010, Zhou et al. 2018).  $T_{\text{regs}}$  were found to control intratumoral eosinophil and basophil infiltration, both of which can promote recruitment of  $CD8^+$  T cells, leading to tumor rejection of melanoma cell lines (Carretero et al. 2015, Sektioğlu et al. 2017). In addition,  $T_{\text{regs}}$  indirectly maintain an immunosuppressive phenotype in TAMs by inhibiting the release of IFN $\gamma$  in the TMEs of inoculated B16 and MC38 tumors (Liu et al. 2019). Up until now, these interactions have not been investigated in the context of breast cancer, illustrating that we have perhaps only scratched the surface on the effector functions of  $T_{\text{regs}}$  in breast cancer. Promisingly, a transcriptional signature specific for tumor-infiltrating  $T_{\text{regs}}$  has revealed remarkable similarity across tumor types in both human and mouse (Magnuson et al. 2018), suggesting that effector mechanisms may be shared across tumor types. Accordingly, the chemokine receptor

CCR8 was identified as part of this signature, supporting previously discussed findings in human breast cancer (Plitas et al. 2016).

#### 4.2. Mechanisms of Intratumoral Accumulation of $T_{\text{regs}}$ in Breast Tumors

Three main hypotheses have been postulated to explain the accumulation of  $T_{\text{regs}}$  in breast tumors. Firstly,  $T_{\text{regs}}$  that circulate in peripheral blood and lymph nodes may migrate into the TME following chemokine gradients upon activation. Secondly, it has been hypothesized that tissue-resident  $T_{\text{regs}}$  locally expand in the TME. Finally, intratumoral conversion of conventional  $CD4^+$  T cells into  $pT_{\text{regs}}$  may represent an important mechanism for  $T_{\text{reg}}$  accumulation. Although these hypotheses are not mutually exclusive and may all contribute to  $T_{\text{reg}}$  accumulation, the migration hypothesis in particular has been supported by experimental evidence. Studies in humans and mice have shown that  $T_{\text{regs}}$  express a wide range of chemokine receptors that may facilitate intratumoral homing, of which CCR2, CCR4, CCR5, CCR8, CXCR3, and CXCR6 have been associated with breast cancer (Plitas et al. 2016, Yano et al. 2019). For example,  $CCR2^+$   $T_{\text{regs}}$  accumulate in multiple tumor models, including the PyMT-MMTV model (Loyher et al. 2016). These cells display an activated phenotype and were found to be tumor-antigen specific in an OVA (ovalbumin)-expressing sarcoma cell line inoculation model. Specific ablation of CCR2 on  $T_{\text{regs}}$  strongly reduced intratumoral  $T_{\text{reg}}$  accumulation (Loyher et al. 2016). CCR2 was also found to be expressed by intratumoral  $T_{\text{regs}}$  in human breast tumors (Plitas et al. 2016). Others have reported high expression of CCR4 by  $T_{\text{regs}}$  in the blood of breast cancer patients, with migratory capabilities to CCL22 and CCL17 (Gobert et al. 2009). As discussed above, CCR8 has emerged as a chemokine receptor expressed uniquely by tumor-associated  $T_{\text{regs}}$  (Plitas et al. 2016, Wang et al. 2019) and has therefore gained attention as a potential therapeutic target. Anti-CCR8 monoclonal antibody (mAb) treatment of mice inoculated with CT26 colon carcinoma cells significantly reduced  $T_{\text{regs}}$  in tumors and enhanced intratumoral IFN $\gamma$  expression (Villarreal et al. 2018). In contrast, others have shown that CCR8 may be redundant for intratumoral  $T_{\text{reg}}$  homing, as adoptively transferred Ccr8-knockout  $T_{\text{regs}}$  in mice inoculated with MC38 colon carcinoma cells did not display reduced potential of migrating into tumors (Magnuson et al. 2018). It has also been reported that autocrine production of CCL1, the ligand for CCR8, potentiates both  $T_{\text{reg}}$  proliferation and suppressive potential (Barsheshet et al. 2017), suggesting that CCR8 may play an important role in maintaining  $T_{\text{reg}}$ -mediated immunosuppression, in addition to its chemotactic properties.

Accumulating evidence shows that intratumoral  $T_{\text{regs}}$  in breast cancer are transcriptionally distinct from  $T_{\text{regs}}$  in peripheral blood and lymph nodes and share gene expression profiles with mammary tissue-resident  $T_{\text{regs}}$  (Azizi et al. 2018, Plitas et al. 2016, Szabo et al. 2019). This suggests either that tissue-resident cells expand in tumors or that the local TME drives transcriptional adaptation of cells migrating into the TME. It has been reported that intratumoral and healthy breast  $T_{\text{regs}}$  within patients showed relatively little overlap of their TCR repertoire, suggesting that intratumoral  $T_{\text{regs}}$  do not derive from resident cells (Plitas et al. 2016). In addition, Ki67 expression in  $T_{\text{regs}}$  of healthy breast tissue was found to be drastically lower than that in  $T_{\text{regs}}$  from tumor or blood. In line with the second notion, single-cell RNA sequencing (scRNA-seq) of  $T_{\text{regs}}$  of naïve mice revealed that  $T_{\text{reg}}$  migration from lymphoid to nonlymphoid tissues indeed induces a transcriptional program specifically tailored to the destined tissue (Miragaia et al. 2019). Furthermore, scRNA-seq of  $CD45^+$  cells sorted from human breast tumors, blood, and lymph nodes uncovered that intratumoral immune cells can acquire diverse phenotypes that are not found in circulation or normal tissue (Azizi et al. 2018). Here, five different  $T_{\text{reg}}$  clusters unique to the TME were identified that expressed gene sets related to activation, anti-inflammation, exhaustion, hypoxia, and metabolism. Together, these studies suggest that transcriptional adaptation of

migratory  $T_{\text{regs}}$  in the TME may explain the transcriptomic resemblance between intratumoral and mammary tissue-resident  $T_{\text{regs}}$ , although further TCR profiling and genetic tracing studies are needed to definitively confirm this.

Research on the accumulation of  $tT_{\text{regs}}$  versus  $pT_{\text{regs}}$  in cancer has been rather limited due to the complexities of distinguishing both  $T_{\text{reg}}$  subsets *in vivo*. Yet, local induction of  $pT_{\text{regs}}$  in the TME may in fact be an important mechanism of immunosuppression, as TGF- $\beta$  is abundantly expressed in cancers (Batlle & Massagué 2019). However, analysis of  $T_{\text{regs}}$  in human glioma, melanoma, and lung cancer samples did not reveal a substantial contribution of  $pT_{\text{regs}}$  to the total intratumoral  $T_{\text{reg}}$  pool (Ahmadzadeh et al. 2019, Akimova et al. 2017, Lowther et al. 2016, Plitas et al. 2016). For example, one study found that the overlap between TCR clonotypes of FOXP3<sup>+</sup> and FOXP3<sup>-</sup> CD4<sup>+</sup> T cells obtained from six melanoma tumors was 0.5–13.2%, indicating that a relatively small proportion of  $T_{\text{regs}}$  may have been  $pT_{\text{regs}}$ . However, others have attributed important roles to  $pT_{\text{regs}}$  in murine cancer models (Alonso et al. 2018, Olkhanud et al. 2011, Schreiber et al. 2012, Su et al. 2017). One of these reports provided indications of their presence in the TME of breast cancer patients (Su et al. 2017). TCR repertoire analysis on CD4<sup>+</sup> T cells from tumor, blood, and lymph nodes of five breast cancer patients revealed that tumor-infiltrating  $T_{\text{regs}}$  are most similar to naïve CD4<sup>+</sup> T cells from tumor and blood, suggesting intratumoral conversion. By using the MDA-MB-231 TNBC cell line in humanized mice, these researchers further showed that TAM-secreted CCL18 specifically recruits naïve CD4<sup>+</sup> T cells, but not  $T_{\text{regs}}$ , via PITPNM3, into the TME. Here, these naïve CD4<sup>+</sup> T cells were capable of converting into FOXP3<sup>+</sup>  $T_{\text{regs}}$ , via unknown mechanisms. Blocking CCL18 in tumor-bearing mice reduced intratumoral  $T_{\text{reg}}$  numbers and inhibited tumor growth (Su et al. 2017). As data on the role of  $pT_{\text{regs}}$  in breast cancer are still limited, future studies should focus on expanding these findings in a larger cohort of patients.

It is now well established that  $T_{\text{regs}}$  have various ways to accumulate in primary tumors. However, breast cancer survival is largely dictated by the extent of metastatic disease. Thus far, we have mostly discussed research on  $T_{\text{regs}}$  in breast cancer in the context of primary tumors, raising questions on the link between primary tumors and metastasis. Can  $T_{\text{regs}}$  impact metastasis formation from within the primary tumor? Or do circulating or tissue-resident  $T_{\text{regs}}$  induce a systemic immunosuppressive axis that impacts metastasis formation?

### 4.3. Impact of $T_{\text{regs}}$ on Metastatic Progression

Primary cancer cells must progress through a multistep process in order to successfully metastasize. This so-called metastatic cascade consists of tumor cell invasion, intravasation, survival in the circulation, extravasation, and outgrowth in a foreign, hostile environment, all while evading destruction by the immune system (Blomberg et al. 2018). Prior to metastatic spread, tumor-derived systemic factors can even further potentiate metastasis by instructing (immature) myeloid cells to establish a premetastatic niche (Kitamura et al. 2015).  $T_{\text{regs}}$  may be involved in all steps of the metastatic cascade through mechanisms both dependent and independent of their immune-regulatory function. However, progress toward understanding their impact on the metastatic cascade is hampered by the limited availability of preclinical models that realistically recapitulate metastasis (Gómez-Cuadrado et al. 2017). Cancer cell line-based mouse models fail to fully recapitulate the chronic and systemic inflammation that underlies *de novo* tumor development, progression, and metastasis (Kersten et al. 2017). In addition, research in both 4T1 and PyMT models has shown that  $T_{\text{reg}}$  depletion reduces primary tumor growth (Bos et al. 2013, Liu et al. 2016), which may obscure mechanisms at play during the metastatic cascade. Indeed, using the 4T1 model, it was recently shown that control of primary tumor growth following  $T_{\text{reg}}$

depletion subsequently led to control of metastatic disease through the induction of protective immunity (Hughes et al. 2020). These data suggest that the potential direct effects of  $T_{\text{regs}}$  on the metastatic cascade are masked in tumor models that are responsive to  $T_{\text{reg}}$  depletion in a primary setting. Nevertheless, several studies have revealed that tumor-induced (systemic) activation of  $T_{\text{regs}}$  can contribute to metastatic progression (**Figure 1**). This activation can be mediated via the release of various tumor-derived soluble factors, such as prostaglandins, complement factors, and  $\beta$ -galactoside-binding proteins (Dalotto-Moreno et al. 2013, Karavitis et al. 2012, Vadrevu et al. 2014). For example, tumor-secreted galectin-1 was reported to enhance systemic expansion of  $T_{\text{regs}}$  and their suppressive potential, resulting in increased lung metastases in mice bearing inoculated 4T1 mammary tumors (Dalotto-Moreno et al. 2013). Others showed that overexpression of COX2 in inoculated TM40D mammary tumors enhanced bone metastasis, which correlated with increased recruitment of  $T_{\text{regs}}$  into the primary tumor (Karavitis et al. 2012). In addition to factors released by the primary tumor, the local (pre)metastatic niche can also play an important role in the activation and recruitment of  $T_{\text{regs}}$ . For example, IL-33 and CCL17 have both been reported to be released in metastatic foci in the lungs of 4T1 tumor-bearing mice, leading to the accumulation of  $T_{\text{regs}}$  that express the receptor for these molecules, thereby promoting metastasis (Halvorsen et al. 2019, Olkhanud et al. 2009).

Various tumor-driven pathways exist to systemically engage  $T_{\text{regs}}$  to the benefit of metastatic spread. An underlying question remains how  $T_{\text{regs}}$  mechanistically contribute to metastasis. Interestingly,  $T_{\text{regs}}$  have been found to directly contribute to metastasis of the 4T1 and MT2 cell lines in mice by promoting tumor cell survival via the release of Rankl and Areg (Halvorsen et al. 2019, Tan et al. 2011). In addition, in line with their immunomodulatory properties, the prometastatic function of  $T_{\text{regs}}$  has been linked to inhibition of cytotoxic immune cells. Indeed,  $T_{\text{reg}}$ -mediated inhibition of NK cells has been associated with increased pulmonary metastasis in the 4T1 model (Biragyn et al. 2013). Others found that neoadjuvant ablation of  $T_{\text{regs}}$  in 4T1 tumor-bearing *Foxp3*<sup>DTR</sup> mice almost completely abolished the formation of lung metastases, which was dependent on both CD4<sup>+</sup> and CD8<sup>+</sup> T cells but not NK cells (Liu et al. 2016). Of note, only neoadjuvant, and not adjuvant,  $T_{\text{reg}}$  depletion increased the systemic frequency and activation of tumor-specific CD8<sup>+</sup> T cells (Liu et al. 2016). It has not been addressed whether CD4<sup>+</sup> T cells directly engage in tumor cell killing in the absence of  $T_{\text{regs}}$ , or whether they perhaps provide essential help for CD8<sup>+</sup> T cell activation. The superiority of neoadjuvant over adjuvant targeting of  $T_{\text{regs}}$  suggests a role for  $T_{\text{regs}}$  in early stages of metastasis, which is supported by observations in breast cancer patients that  $T_{\text{reg}}$  accumulation associates with metastasis formation in draining lymph nodes (Faghih et al. 2014, Jiang et al. 2015, Núñez et al. 2020).

Several clinical studies have reported that high  $T_{\text{reg}}$  infiltration in primary tumors and sentinel lymph nodes is associated with the occurrence of lymph node metastasis (**Table 1**), but mechanistic data are limited. So far, one study has linked intranodal  $T_{\text{regs}}$  to breast cancer progression in mice. Here, in a 4T1 model,  $T_{\text{reg}}$ -derived TGF- $\beta$ 1 induced IL-17RB in cancer cells in TDLNs (Huang et al. 2017). IL-17RB was found to potentiate the metastatic and colony-forming potential of cancer cells via NF- $\kappa$ B, which enhanced distant metastasis. Interestingly, analysis of IL-17RB expression in lymph node metastasis and matched tumors of breast cancer patients confirmed that IL-17RB is increased in lymph nodes and correlates with FOXP3 frequency (Huang et al. 2017). This study revealed that the TDLNs in breast cancer can function as a gateway to distant metastasis, with  $T_{\text{regs}}$  corrupted by the primary tumor. These findings raise the question whether  $T_{\text{regs}}$  are also involved in cancer cell dissemination to the draining lymph node. It has recently been reported that B cells promote metastasis to draining lymph nodes in the 4T1 and MMTV-PyMT models via the release of HSP4A-binding antibodies that directly promote tumor cell migration (Gu et al. 2019). Interestingly, B cell depletion did significantly reduce tumor-induced  $T_{\text{reg}}$

accumulation in TDLNs. In line with these findings, it has previously been reported that regulatory B cells that accumulate in 4T1 tumor-bearing mice can induce pT<sub>regs</sub> in a TGF- $\beta$ -dependent manner (Olkhanud et al. 2011), revealing an interesting cross talk between T<sub>regs</sub> and B cells in breast cancer metastasis.

## 5. FUTURE PROSPECTS

T<sub>regs</sub> have taken an increasingly important position in our understanding of the immune system in breast cancer. Preclinical research has revealed ingenious mechanisms employed by breast tumors to seize control of T<sub>regs</sub> for their own benefit. In parallel, in-depth characterization of T<sub>regs</sub> beyond traditional FOXP3 scoring in human samples is paving the way to advance the prognostic and predictive value of T<sub>regs</sub> in the clinic. Here, future efforts should focus on further defining the heterogeneity of T<sub>regs</sub> and evaluate which features of T<sub>regs</sub> are instrumental for disease progression, while also expanding current findings to HR<sup>-</sup> subtypes of breast cancer where T<sub>regs</sub> are associated with a good prognosis. As the use of immunomodulatory drugs is gaining momentum in the clinic, interrogating these observations in the context of immunotherapy is also an important next step.

The context dependency under which T<sub>regs</sub> operate should also be increasingly taken into account in preclinical research. Until now the majority of research has been performed in a limited number of (cell line-based) breast cancer models, often with unclear translatability to human disease. An important challenge to address here is that breast cancer patients suffer from metastatic spread to a broad spectrum of anatomical locations, while experimental metastasis in animal models is often limited to the lungs. A crucial next step is therefore to validate preclinical findings in murine models that have increased translatability, in terms of both cancer subtype and metastasis formation. To achieve this, one must realize that the interaction between the immune system and cancer may even be more complex than initially assumed. We are only now beginning to understand that the genetic makeup of tumors may profoundly impact their accompanying TME (Wellenstein & de Visser 2018). In addition, in-depth analyses of 168 metastatic and primary tumor samples from 10 breast cancer patients has revealed that the composition of metastatic TMEs within patients is heterogeneous, even within particular organs. Moreover, the expression of genes encoding immunomodulatory proteins such as PD-1 and PD-L1 differs across metastases within individual patients (De Mattos-Arruda et al. 2019). These complexities of human metastatic disease illustrate the need for accurate models of metastasis.

Ultimately, these fundamental insights into the role of T<sub>regs</sub> in breast cancer progression could form the basis for therapeutic intervention. As such, several early phase clinical trials have evaluated the FDA (US Food and Drug Administration)-approved mAb daclizumab (anti-CD25) in combination with cancer vaccines in metastatic melanoma and breast cancer (Jacobs et al. 2010, Rech et al. 2012). FOXP3<sup>+</sup> CD4<sup>+</sup> T cells in peripheral blood were found to be reduced upon daclizumab treatment, but no significant clinical benefit was observed. However, daclizumab does not induce antibody-dependent cytotoxicity (ADCC), which others have suggested to be essential for intratumoral T<sub>reg</sub> depletion and therapeutic efficacy (Arce Vargas et al. 2017, Rech et al. 2012). Recently, an optimized ADCC-inducing anti-CD25 antibody showed superior intratumoral T<sub>reg</sub> depletion and induced CD8<sup>+</sup> T cell-mediated tumor rejection in combination with anti-PD-1 therapy in preclinical models (Arce Vargas et al. 2017). Alternatively, intratumoral injection of CD25-targeting immunotoxins also potently depletes intratumoral T<sub>regs</sub>, leading to CD8<sup>+</sup> T cell-mediated tumor regression of inoculated 66c14 breast cancer tumors (Onda et al. 2019). Importantly, these preclinical results suggest that effector T cell responses are not necessarily negatively impacted by CD25-based depletion, which may set the stage for clinical trials evaluating this new generation of T<sub>reg</sub>-targeting strategies. In addition to T<sub>reg</sub> depletion, blocking of their

intratumoral recruitment, conversion, or important effector mechanisms may be alternative future approaches to interfere with T<sub>reg</sub>-mediated modulation of breast cancer (Plitas & Rudensky 2020).

In conclusion, recent research has revealed T<sub>regs</sub> as important modulators of breast cancer progression and metastasis, and exciting advancements in clinical analysis have improved the prognostic and predictive significance of these cells and the therapeutic potential of targeting them. The use of GEMMs that closely mimic the diversity and the stepwise progression of human breast cancer subtypes will propel our understanding of T<sub>reg</sub> biology to a higher level and deepen our knowledge of underlying mechanisms. This knowledge could help researchers take full advantage of novel immunomodulatory drugs that may take the stage in breast cancer treatment.

## DISCLOSURE STATEMENT

K.E.d.V. reports research funding from Roche and is a consultant for Third Rock Ventures, both of which are outside the scope of this work. K.K. reports no competing interests.

## ACKNOWLEDGMENTS

We would like to thank Max Wellenstein and Wietske Pieters for insightful comments during the writing process. Research in the De Visser laboratory is funded by the Netherlands Organization for Scientific Research (grant NWO-VICI 91819616), the Dutch Cancer Society (KWF10083, KWF10623), a European Research Council Consolidator award (InflaMet 615300), and Oncode Institute. K.K. is funded by the NWO Oncology Graduate School Amsterdam (OOA) Diamond Program.

## LITERATURE CITED

- Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, et al. 2019. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. *Ann. Oncol.* 30(3):405–11
- Ahmazadeh M, Pasetto A, Jia L, Deniger DC, Stevanović S, et al. 2019. Tumor-infiltrating human CD4<sup>+</sup> regulatory T cells display a distinct TCR repertoire and exhibit tumor and neoantigen reactivity. *Sci. Immunol.* 4(31):eaao4310
- Akimova T, Zhang T, Negorev D, Singhal S, Stadanlick J, et al. 2017. Human lung tumor FOXP3<sup>+</sup> Tregs upregulate four “Treg-locking” transcription factors. *JCI Insight* 2(16):e94075
- Allaoui R, Hagerling C, Desmond E, Warfvinge CF, Jirstrom K, Leandersson K. 2017. Infiltration of  $\gamma\delta$  T cells, IL-17<sup>+</sup> T cells and FoxP3<sup>+</sup> T cells in human breast cancer. *Cancer Biomarkers* 20(4):395–409
- Alonso R, Flament H, Lemoine S, Sedlik C, Bottasso E, et al. 2018. Induction of anergic or regulatory tumor-specific CD4<sup>+</sup> T cells in the tumor-draining lymph node. *Nat. Commun.* 9:2113
- Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, et al. 2017. Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors. *Immunity* 46(4):577–86
- Azizi E, Carr AJ, Plitas G, Cornish AE, Konopacki C, et al. 2018. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. *Cell* 174(5):1293–308.e36
- Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. 2001. CD4<sup>+</sup>CD25<sup>high</sup> regulatory cells in human peripheral blood. *J. Immunol.* 167(3):1245–53
- Barsheshet Y, Wildbaum G, Levy E, Vitsenshtein A, Akinseye C, et al. 2017. CCR8<sup>+</sup>FOXP3<sup>+</sup> T<sub>reg</sub> cells as master drivers of immune regulation. *PNAS* 114(23):6086–91
- Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, et al. 2006. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. *J. Clin. Oncol.* 24(34):5373–80

- Battle E, Massagué J. 2019. Transforming growth factor- $\beta$  signaling in immunity and cancer. *Immunity* 50(4):924–40
- Bentzon N, Düring M, Rasmussen BB, Mouridsen H, Kroman N. 2007. Prognostic effect of estrogen receptor status across age in primary breast cancer. *Int. J. Cancer* 122(5):1089–94
- Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, et al. 2018. Understanding the tumor immune microenvironment (TIME) for effective therapy. *Nat. Med.* 24(5):541–50
- Biragyn A, Bodogai M, Olkhanud PB, Denny-Brown SR, Puri N, et al. 2013. Inhibition of lung metastasis by chemokine CCL17-mediated in vivo silencing of genes in CCR4<sup>+</sup> Tregs. *J. Immunother.* 36(4):258–67
- Blatner NR, Bonertz A, Beckhove P, Cheon EC, Krantz SB, et al. 2010. In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. *PNAS* 107(14):6430–35
- Blomberg OS, Spagnuolo L, De Visser KE. 2018. Immune regulation of metastasis: mechanistic insights and therapeutic opportunities. *Dis. Model. Mech.* 11(10):dmm036236
- Bluestone JA, Bour-Jordan H, Cheng M, Anderson M. 2015. T cells in the control of organ-specific autoimmunity. *J. Clin. Investig.* 125(6):2250–60
- Bos PD, Plitas G, Rudra D, Lee SY, Rudensky AY. 2013. Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. *J. Exp. Med.* 210(11):2435–66
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* 68(6):394–424
- Brunkow ME, Jeffery EW, Hjerrild KA, Paepfer B, Clark LB, et al. 2001. Disruption of a new forkhead/winged-helix protein, scurfy, results in the fatal lymphoproliferative disorder of the scurfy mouse. *Nat. Genet.* 27:68–73
- Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, Hämmerling GJ. 2015. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8<sup>+</sup> T cells. *Nat. Immunol.* 16(6):609–17
- Chinen T, Kannan AK, Levine AG, Fan X, Klein U, et al. 2016. An essential role for the IL-2 receptor in T<sub>reg</sub> cell function. *Nat. Immunol.* 17(11):1322–33
- Coe D, Begom S, Addey C, White M, Dyson J, Chai JG. 2010. Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. *Cancer Immunol. Immunother.* 59(9):1367–77
- Curotto de Lafaille MA, Lafaille JJ. 2009. Natural and adaptive Foxp3<sup>+</sup> regulatory T cells: more of the same or a division of labor? *Immunity* 30(5):626–35
- Dalotto-Moreno T, Croci DO, Cerliani JP, Martinez-Allo VC, Dergan-Dylon S, et al. 2013. Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. *Cancer Res.* 73(3):1107–17
- De Mattos-Arruda L, Sammut SJ, Ross EM, Bashford-Rogers R, Greenstein E, et al. 2019. The genomic and immune landscapes of lethal metastatic breast cancer. *Cell Rep.* 27(9):2690–708.e10
- Decker T, Fischer G, Bücke W, Bücke P, Stotz F, et al. 2012. Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neu-positive early breast cancer. *J. Cancer Res. Clin. Oncol.* 138(11):1945–50
- DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, et al. 2009. CD4<sup>+</sup> T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. *Cancer Cell* 16(2):91–102
- Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, et al. 2018. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. *Lancet Oncol.* 19(1):40–50
- DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, et al. 2019. Breast cancer statistics, 2019. *CA Cancer J. Clin.* 69(6):438–51
- DiDomenico J, Lamano JB, Oyon D, Li Y, Veliceasa D, et al. 2018. The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma. *OncolImmunology* 7(7):e1448329
- Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, et al. 2018. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study. *Breast Cancer Res. Treat.* 167(3):671–86

- Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, et al. 2019. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. *JAMA Oncol.* 5(1):74–82
- Esterházy D, Canesso MCC, Mesin L, Muller PA, de Castro TBR, et al. 2019. Compartmentalized gut lymph node drainage dictates adaptive immune responses. *Nature* 569(7754):126–30
- Faghhi Z, Erfani N, Haghshenas MR, Safaei A, Talei A-R, Ghaderi A. 2014. Immune profiles of CD4<sup>+</sup> lymphocyte subsets in breast cancer tumor draining lymph nodes. *Immunol. Lett.* 158:57–65
- Fontenot JD, Gavin MA, Rudensky AY. 2003. Foxp3 programs the development and function of CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells. *Nat. Immunol.* 4:330–36
- Garner H, de Visser KE. 2020. Immune crosstalk in cancer progression and metastatic spread: a complex conversation. *Nat. Rev. Immunol.* 20(8):482–97
- Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, et al. 2009. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. *Cancer Res.* 69(5):2000–9
- Gómez-Cuadrado L, Tracey N, Ma R, Qian B, Brunton VG. 2017. Mouse models of metastasis: progress and prospects. *Dis. Model. Mech.* 10(9):1061–74
- Goudin N, Chappert P, Mégret J, Gross DA, Rocha B, Azogui O. 2016. Depletion of regulatory T cells induces high numbers of dendritic cells and unmasks a subset of anti-tumour CD8<sup>+</sup>CD11c<sup>+</sup> PD-1<sup>lo</sup> effector T cells. *PLOS ONE* 11(6):e0157822
- Gu Y, Liu Y, Fu L, Zhai L, Zhu J, et al. 2019. Tumor-educated B cells selectively promote breast cancer lymph node metastasis by HSPA4-targeting IgG. *Nat. Med.* 25(2):312–22
- Halvorsen EC, Franks SE, Wadsworth BJ, Harbourne BT, Cederberg RA, et al. 2019. IL-33 increases ST2<sup>+</sup> Tregs and promotes metastatic tumour growth in the lungs in an amphiregulin-dependent manner. *OncImmunology* 8(2):e1527497
- Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. *Cell* 144(5):646–74
- Hori S, Nomura T, Sakaguchi S. 2003. Control of regulatory T cell development by the transcription factor *Foxp3*. *Science* 299(5609):1057–61
- Horlock C, Stott B, Dyson PJ, Morishita M, Coombes RC, et al. 2009. The effects of trastuzumab on the CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup> and CD4<sup>+</sup>IL17A<sup>+</sup> T-cell axis in patients with breast cancer. *Br. J. Cancer* 100(7):1061–67
- Huang AC, Orłowski RJ, Xu X, Mick R, George SM, et al. 2019. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. *Nat. Med.* 25(3):454–61
- Huang S, Wei P, Hwang-Verslues WW, Kuo W, Jeng Y, et al. 2017. TGF-β1 secreted by Tregs in lymph nodes promotes breast cancer malignancy via up-regulation of IL-17RB. *EMBO Mol. Med.* 9(12):1660–80
- Hughes E, Lauder SN, Smart K, Bloom A, Scott J, et al. 2020. Primary breast tumours but not lung metastases induce protective anti-tumour immune responses after Treg-depletion. *Cancer Immunol. Immunother.* 69:2063–73
- Jacobs JFM, Punt CJA, Lesterhuis WJ, Suttmuller RPM, Brouwer HMLH, et al. 2010. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. *Clin. Cancer Res.* 16(20):5067–78
- Jang JE, Hajdu CH, Liot C, Miller G, Dustin ML, Bar-Sagi D. 2017. Crosstalk between regulatory T cells and tumor-associated dendritic cells negates anti-tumor immunity in pancreatic cancer. *Cell Rep.* 20(3):558–71
- Jiang D, Gao Z, Cai Z, Wang M, He J. 2015. Clinicopathological and prognostic significance of FOXP3<sup>+</sup> tumor infiltrating lymphocytes in patients with breast cancer: a meta-analysis. *BMC Cancer* 15:727
- Jordan MS, Boesteanu A, Reed AJ, Petrone AL, Holenbeck AE, et al. 2001. Thymic selection of CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells induced by an agonist self-peptide. *Nat. Immunol.* 2(4):301–6
- Josefowicz SZ, Lu L-F, Rudensky AY. 2012a. Regulatory T cells: mechanisms of differentiation and function. *Annu. Rev. Immunol.* 30:531–64
- Josefowicz SZ, Niec RE, Kim HY, Treuting P, Chinen T, et al. 2012b. Extrathymically generated regulatory T cells control mucosal TH2 inflammation. *Nature* 482(7385):395–99
- Kalekar LA, Schmiel SE, Nandiwada SL, Lam WY, Barsness LO, et al. 2016. CD4<sup>+</sup> T cell anergy prevents autoimmunity and generates regulatory T cell precursors. *Nat. Immunol.* 17(3):304–14



- Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, et al. 2019. PD-1<sup>+</sup> regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. *PNAS* 116(20):9999–10008
- Kanamori M, Nakatsukasa H, Okada M, Lu Q, Yoshimura A. 2016. Induced regulatory T cells: their development, stability, and applications. *Trends Immunol.* 37(11):803–11
- Karavitis J, Hix LM, Shi YH, Schultz RF, Khazaie K, Zhang M. 2012. Regulation of COX2 expression in mouse mammary tumor cells controls bone metastasis and PGE2-induction of regulatory T cell migration. *PLOS ONE* 7(9):e46342
- Kersten K, de Visser KE, van Miltenburg MH, Jonkers J. 2017. Genetically engineered mouse models in oncology research and cancer medicine. *EMBO Mol. Med.* 9(2):137–53
- Kieback E, Hilgenberg E, Stervbo U, Lampropoulou V, Shen P, et al. 2016. Thymus-derived regulatory T cells are positively selected on natural self-antigen through cognate interactions of high functional avidity. *Immunity* 44(5):1114–26
- Kim I, Sanchez K, McArthur HL, Page D. 2019. Immunotherapy in triple-negative breast cancer: present and future. *Curr. Breast Cancer Rep.* 11:259–271
- Kim JM, Rasmussen JP, Rudensky AY. 2007. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. *Nat. Immunol.* 8(2):191–97
- Kim ST, Jeong H, Woo OH, Seo JH, Kim A, et al. 2013. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. *Am. J. Clin. Oncol.* 36(3):224–31
- Kitamura T, Qian BZ, Pollard JW. 2015. Immune cell promotion of metastasis. *Nat. Rev. Immunol.* 15(2):73–86
- Koizumi S, Ishikawa H. 2019. Transcriptional regulation of differentiation and functions of effector T regulatory cells. *Cells* 8(8):939
- Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakamura H, et al. 2020. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. *Nat. Immunol.* 21:1346–58
- Lahl K, Loddenkemper C, Drouin C, Freyer J, Arnason J, et al. 2007. Selective depletion of Foxp3<sup>+</sup> regulatory T cells induces a scurfy-like disease. *J. Exp. Med.* 204(1):57–63
- Lee S, Cho EY, Park YH, Ahn JS, Im YH. 2013. Prognostic impact of FOXP3 expression in triple-negative breast cancer. *Acta Oncol.* 52(1):73–81
- Lee W, Lee GR. 2018. Transcriptional regulation and development of regulatory T cells. *Exp. Mol. Med.* 50:e456
- Legoux FP, Lim J-B, Cauley AW, Dikiy S, Ertelt J, et al. 2015. CD4<sup>+</sup> T cell tolerance to tissue-restricted self antigens is mediated by antigen-specific regulatory T cells rather than deletion. *Immunity* 43(5):896–908
- Leonard JD, Gilmore DC, Dileepan T, Jenkins MK, Adams EJ, et al. 2017. Identification of natural regulatory T cell epitopes reveals convergence on a dominant autoantigen. *Immunity* 47:107–17.e8
- Liu C, Chikina M, Deshpande R, Menk AV, Wang T, et al. 2019. Treg cells promote the SREBP1-dependent metabolic fitness of tumor-promoting macrophages via repression of CD8<sup>+</sup> T cell-derived interferon- $\gamma$ . *Immunity* 51(2):381–97.e6
- Liu F, Lang R, Zhao J, Zhang X, Pringle GA, et al. 2011. CD8<sup>+</sup> cytotoxic T cell and FOXP3<sup>+</sup> regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. *Breast Cancer Res. Treat.* 130(2):645–55
- Liu J, Blake SJ, Yong MCR, Harjunpää H, Ngiow SF, et al. 2016. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. *Cancer Discov.* 6(12):1382–99
- Liu S, Foulkes WD, Leung S, Gao D, Lau S, et al. 2014. Prognostic significance of FOXP3<sup>+</sup> tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. *Breast Cancer Res.* 16(5):432
- Liyanage UK, Moore TT, Joo H-G, Tanaka Y, Herrmann V, et al. 2002. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. *J. Immunol.* 169(5):2756–61
- Loebbermann J, Thornton H, Durant L, Sparwasser T, Webster KE, et al. 2012. Regulatory T cells expressing granzyme B play a critical role in controlling lung inflammation during acute viral infection. *Mucosal Immunol.* 5(2):161–72
- Lowther DE, Goods BA, Lucca LE, Lerner BA, Raddassi K, et al. 2016. PD-1 marks dysfunctional regulatory T cells in malignant gliomas. *JCI Insight* 1(5):e85935

- Loyher PL, Rochefort J, Baudesson De Chanville C, Hamon P, Lescaille G, et al. 2016. CCR2 influences T regulatory cell migration to tumors and serves as a biomarker of cyclophosphamide sensitivity. *Cancer Res.* 76(22):6483–94
- Lucca LE, Dominguez-Villar M. 2020. Modulation of regulatory T cell function and stability by co-inhibitory receptors. *Nat. Rev. Immunol.* 20:680–93
- Maeda N, Yoshimura K, Yamamoto S, Kuramasu A, Inoue M, et al. 2014. Expression of B7-H3, a potential factor of tumor immune evasion in combination with the number of regulatory T cells, affects against recurrence-free survival in breast cancer patients. *Ann. Surg. Oncol.* 21(4):546–54
- Magnuson AM, Kiner E, Ergun A, Park JS, Asinovski N, et al. 2018. Identification and validation of a tumor-infiltrating Treg transcriptional signature conserved across species and tumor types. *PNAS* 115(45):E10672–81
- Mahmoud SMA, Paish EC, Powe DG, MacMillan RD, Lee AHS, et al. 2011. An evaluation of the clinical significance of FOXP3<sup>+</sup> infiltrating cells in human breast cancer. *Breast Cancer Res. Treat.* 127:99–108
- Malhotra D, Linehan JL, Dileepan T, Lee YJ, Purtha WE, et al. 2016. Tolerance is established in polyclonal CD4<sup>+</sup> T cells by distinct mechanisms, according to self-peptide expression patterns. *Nat. Immunol.* 17(2):187–95
- Marie JC, Letterio JJ, Gavin M, Rudensky AY. 2005. TGF- $\beta$ 1 maintains suppressor function and Foxp3 expression in CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells. *J. Exp. Med.* 201(7):1061–67
- Martinez LM, Robila V, Clark NM, Du W, Idowu MO, et al. 2019. Regulatory T cells control the switch from *in situ* to invasive breast cancer. *Front. Immunol.* 10:1942
- Miragaia RJ, Gomes T, Chomka A, Jardine L, Riedel A, et al. 2019. Single-cell transcriptomics of regulatory T cells reveals trajectories of tissue adaptation. *Immunity* 50(2):493–504.e7
- Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, et al. 2009. Functional delineation and differentiation dynamics of human CD4<sup>+</sup> T cells expressing the FoxP3 transcription factor. *Immunity* 30(6):899–911
- Miyashita M, Sasano H, Tamaki K, Hirakawa H, Takahashi Y, et al. 2015. Prognostic significance of tumor-infiltrating CD8<sup>+</sup> and FOXP3<sup>+</sup> lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. *Breast Cancer Res.* 17:124
- Moran AE, Holzapfel KL, Xing Y, Cunningham NR, Maltzman JS, et al. 2011. T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse. *J. Exp. Med.* 208(6):1279–89
- Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson CC. 2010. Regulatory T cells in cancer. *Adv. Cancer Res.* 107:57–117
- Nanda R, Chow LQM, Dees EC, Berger R, Gupta S, et al. 2016. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. *J. Clin. Oncol.* 34(21):2460–67
- Núñez NG, Boari JT, Ramos RN, Richer W, Cagnard N, et al. 2020. Tumor invasion in draining lymph nodes is associated with Treg accumulation in breast cancer patients. *Nat. Commun.* 11:3272
- Olkhanud PB, Baatar D, Bodogai M, Hakim F, Gress R, et al. 2009. Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. *Cancer Res.* 69(14):5996–6004
- Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, et al. 2011. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4<sup>+</sup> T cells to T-regulatory cells. *Cancer Res.* 71(10):3505–15
- Onda M, Kobayashi K, Pastan I. 2019. Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity. *PNAS* 116(10):4575–82
- Özdemir BC, Sflomos G, Briskin C. 2018. The challenges of modeling hormone receptor-positive breast cancer in mice. *Endocr. Relat. Cancer* 25(5):319–30
- Papaioannou E, Sakellakis M, Melachrinou M, Tzoracoleftherakis E, Kalofonos H, Kourea E. 2019. A standardized evaluation method for FOXP3<sup>+</sup> Tregs and CD8<sup>+</sup> T-cells in breast carcinoma: association with breast carcinoma subtypes, stage and prognosis. *Anticancer Res.* 39(3):1217–32
- Peng GL, Li L, Guo YW, Yu P, Yin XJ, et al. 2019. CD8<sup>+</sup> cytotoxic and FoxP3<sup>+</sup> regulatory T lymphocytes serve as prognostic factors in breast cancer. *Am. J. Transl. Res.* 11(8):5039–53

- Perez SA, Karamouzis MV, Skarlos DV, Ardavanis A, Sotiriadou NN, et al. 2007. CD4<sup>+</sup>CD25<sup>+</sup> regulatory T-cell frequency in HER-2/*neu* (HER)-positive and HER-negative advanced-stage breast cancer patients. *Clin. Cancer Res.* 13(9):2714–21
- Planes-Laine G, Rochigneux P, Bertucci F, Chrétien AS, Viens P, et al. 2019. PD-1/PD-L1 targeting in breast cancer: The first clinical evidences are emerging—a literature review. *Cancers* 11(7):e1033
- Plitas G, Konopacki C, Wu K, Bos PD, Morrow M, et al. 2016. Regulatory T cells exhibit distinct features in human breast cancer. *Immunity* 45(5):1122–34
- Plitas G, Rudensky AY. 2020. Regulatory T cells in cancer. *Annu. Rev. Cancer Biol.* 4:459–77
- Qiu SQ, Waaijer SJH, Zwager MC, de Vries EGE, van der Veegt B, Schröder CP. 2018. Tumor-associated macrophages in breast cancer: innocent bystander or important player? *Cancer Treat. Rev.* 70:178–89
- Rech AJ, Mick R, Martin S, Recio A, Aqui NA, et al. 2012. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. *Sci. Transl. Med.* 4(134):134ra62
- Roncador G, Brown PJ, Maestre L, Hue S, Martínez-Torrecuadrada JL, et al. 2005. Analysis of FOXP3 protein expression in human CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells at the single-cell level. *Eur. J. Immunol.* 35(6):1681–91
- Russell WL, Russell LB, Gower JS. 1959. Exceptional inheritance of a sex-linked gene in the mouse explained on the basis that the X/O sex chromosome constitution is female. *PNAS* 45(4):554–60
- Sakaguchi S, Yamaguchi T, Nomura T, Ono M. 2008. Regulatory T cells and immune tolerance. *Cell* 133(5):775–87
- Sawant DV, Yano H, Chikina M, Zhang Q, Liao M, et al. 2019. Adaptive plasticity of IL-10<sup>+</sup> and IL-35<sup>+</sup> Treg cells cooperatively promotes tumor T cell exhaustion. *Nat. Immunol.* 20(6):724–35
- Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, et al. 2018. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. *N. Engl. J. Med.* 379(22):2108–21
- Schreiber TH, Wolf D, Boderer M, Podack E. 2012. Tumor antigen specific iTreg accumulate in the tumor microenvironment and suppress therapeutic vaccination. *OncolImmunology* 1(5):642–48
- Sektioğlu IM, Carretero R, Bulbuc N, Bald T, Tütting T, et al. 2017. Basophils promote tumor rejection via chemotaxis and infiltration of CD8<sup>+</sup> T cells. *Cancer Res.* 77(2):291–302
- Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, et al. 2013. Tumour-infiltrating CD8<sup>+</sup> lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. *Br. J. Cancer* 109(10):2705–13
- Sharma A, Rudra D. 2018. Emerging functions of regulatory T cells in tissue homeostasis. *Front. Immunol.* 9:883
- Soroosh P, Doherty TA, Duan W, Mehta AK, Choi H, et al. 2013. Lung-resident tissue macrophages generate Foxp3<sup>+</sup> regulatory T cells and promote airway tolerance. *J. Exp. Med.* 210(4):775–88
- Su S, Liao J, Liu J, Huang D, He C, et al. 2017. Blocking the recruitment of naive CD4<sup>+</sup> T cells reverses immunosuppression in breast cancer. *Cell Res.* 27(4):461–82
- Sun S, Fei X, Mao Y, Wang X, Garfield DH, et al. 2014. PD-1<sup>+</sup> immune cell infiltration inversely correlates with survival of operable breast cancer patients. *Cancer Immunol. Immunother.* 63(4):395–406
- Syed Khaja AS, Toor SM, El Salhat H, Faour I, Ul Haq N, et al. 2017. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment. *Oncotarget* 8(20):33159–71
- Szabo PA, Levitin HM, Miron M, Snyder ME, Senda T, et al. 2019. Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease. *Nat. Commun.* 10:4706
- Szurek E, Cebula A, Wojciech L, Pietrzak M, Rempala G, et al. 2015. Differences in expression level of helios and neuropilin-1 do not distinguish thymus-derived from extrathymically-induced CD4<sup>+</sup>Foxp3<sup>+</sup> regulatory T cells. *PLOS ONE* 10(10):e0141161
- Takenaka M, Seki N, Toh U, Hattori S, Kawahara A, et al. 2013. FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis. *Mol. Clin. Oncol.* 1(4):625–32
- Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, et al. 2011. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. *Nature* 470(7335):548–53
- Taylor NA, Vick SC, Iglesia MD, Brickey WJ, Midkiff BR, et al. 2017. Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer. *J. Clin. Investig.* 127(9):3472–83

- Togashi Y, Shitara K, Nishikawa H. 2019. Regulatory T cells in cancer immunosuppression—implications for anticancer therapy. *Nat. Rev. Clin. Oncol.* 16(6):356–71
- Tsang JYS, Hui SW, Ni YB, Chan SK, Yamaguchi R, et al. 2014. Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers. *Breast Cancer Res. Treat.* 143:1–9
- Vadrevu SK, Chintala NK, Sharma SK, Sharma P, Cleveland C, et al. 2014. Complement C5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche. *Cancer Res.* 74(13):3454–65
- Vignali DAA, Collison LW, Workman CJ. 2008. How regulatory T cells work. *Nat. Rev. Immunol.* 8(7):523–32
- Villarreal DO, L'Huillier A, Armington S, Mottershead C, Filippova EV, et al. 2018. Targeting CCR8 induces protective antitumor immunity and enhances vaccine-induced responses in colon cancer. *Cancer Res.* 78(18):5340–48
- Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, et al. 2019. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. *Nat. Med.* 25(6):920–28
- Wang L, Simons DL, Lu X, Tu TY, Solomon S, et al. 2019. Connecting blood and intratumoral Treg cell activity in predicting future relapse in breast cancer. *Nat. Immunol.* 20(9):1220–30
- Wang Y, Sun J, Qu X. 2016. Regulatory T cells are an important prognostic factor in breast cancer: a systematic review and meta-analysis. *Neoplasma* 63(5):789–98
- Wei SC, Duffy CR, Allison JP. 2018. Fundamental mechanisms of immune checkpoint blockade therapy. *Cancer Discov.* 8(9):1069–86
- Wellenstein MD, de Visser KE. 2018. Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape. *Immunity* 48(3):399–416
- West NR, Kost SE, Martin SD, Milne K, deLeeuw RJ, et al. 2013. Tumour-infiltrating FOXP3<sup>+</sup> lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. *Br. J. Cancer* 108:155–62
- Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstien B. 2003. Increase of regulatory T cells in the peripheral blood of cancer patients. *Clin. Cancer Res.* 9(2):606–12
- Yamaguchi T, Hirota K, Nagahama K, Ohkawa K, Takahashi T, et al. 2007. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. *Immunity* 27(1):145–59
- Yan M, Jene N, Byrne D, Millar EK, O'Toole SA, et al. 2011. Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. *Breast Cancer Res.* 13(2):R47
- Yano H, Andrews LP, Workman CJ, Vignali DAA. 2019. Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity. *Immunology* 157(3):232–47
- Zhang Y, Lazarus J, Steele NG, Yan W, Lee H-J, et al. 2020. Regulatory T cell depletion alters the tumor microenvironment and accelerates pancreatic carcinogenesis. *Cancer Discov.* 10(3):422–39
- Zheng Y, Josefowicz S, Chaudhry A, Peng XP, Forbush K, Rudensky AY. 2010. Role of conserved non-coding DNA elements in the *Foxp3* gene in regulatory T-cell fate. *Nature* 463(7282):808–12
- Zhou J, Li X, Wu X, Zhang T, Zhu Q, et al. 2018. Exosomes released from tumor-associated macrophages transfer miRNAs that induce a Treg/Th17 cell imbalance in epithelial ovarian cancer. *Cancer Immunol. Res.* 6(12):1578–92
- Zhou Y, Shao N, Aierken N, Xie C, Ye R, et al. 2017. Prognostic value of tumor-infiltrating Foxp3<sup>+</sup> regulatory T cells in patients with breast cancer: a meta-analysis. *J. Cancer* 8(19):4098–105



# Contents

Zena Werb (1945–2020): Matrix Metalloproteinases, Microenvironments, and Mentoring <i>Mikala Egeblad</i> .....	1
Myeloid-Derived Suppressor Cells: Facilitators of Cancer and Obesity-Induced Cancer <i>Suzanne Ostrand-Rosenberg</i> .....	17
Ex Vivo Analysis of Primary Tumor Specimens for Evaluation of Cancer Therapeutics <i>Cristina E. Tognon, Rosalie C. Sears, Gordon B. Mills, Joe W. Gray, and Jeffrey W. Tyner</i> .....	39
Telomeres and Cancer: Resolving the Paradox <i>Joe Nassour, Tobias T. Schmidt, and Jan Karlseder</i> .....	59
Molecular Heterogeneity and Evolution in Breast Cancer <i>Jennifer L. Caswell-Jin, Carina Lorenz, and Christina Curtis</i> .....	79
Molecular Biology of Childhood Leukemia <i>Thomas B. Alexander and Charles G. Mullighan</i> .....	95
Humanized Mouse Models to Evaluate Cancer Immunotherapeutics <i>Silvia Guil-Luna, Christine Sedlik, and Eliane Piaggio</i> .....	119
Immunometabolism in the Tumor Microenvironment <i>Dominic G. Roy, Irem Kaymak, Kelsey S. Williams, Eric H. Ma, and Russell G. Jones</i> .....	137
Nutritional Preconditioning in Cancer Treatment in Relation to DNA Damage and Aging <i>Winnie M.C. van den Boogaard, Marry M. van den Heuvel-Eibrink, Jan H. J. Hoeijmakers, and Wilbert P. Vermeij</i> .....	161
Small-Molecule Approaches to Targeted Protein Degradation <i>Tyler B. Faust, Katherine A. Donovan, Hong Yue, Philip P. Chamberlain, and Eric S. Fischer</i> .....	181
Cancer Immunotherapy and the Nectin Family <i>Robert J. Johnston, Peter S. Lee, Pavel Strop, and Mark J. Smyth</i> .....	203

Mutant Allele Imbalance in Cancer <i>Craig M. Bielski and Barry S. Taylor</i> .....	221
The Bidirectional Relationship Between Cancer Epigenetics and Metabolism <i>Luke T. Izzo, Hayley C. Affronti, and Kathryn E. Wellen</i> .....	235
Personal Neoantigen Vaccines for the Treatment of Cancer <i>Keerthi Shetty and Patrick A. Ott</i> .....	259
The Intriguing Clinical Success of BCL-2 Inhibition in Acute Myeloid Leukemia <i>Daniel A. Pollyea, Shanshan Pei, Brett M. Stevens, Clayton A. Smith, and Craig T. Jordan</i> .....	277
The Multifaceted Role of Regulatory T Cells in Breast Cancer <i>Kevin Kos and Karin E. de Visser</i> .....	291
The Role of Epigenetic Mechanisms in B Cell Lymphoma Pathogenesis <i>Leandro Venturutti and Ari M. Melnick</i> .....	311
Reeling in the Zebrafish Cancer Models <i>Alicia M. McConnell, Haley R. Noonan, and Leonard I. Zon</i> .....	331
Developmental Insights into Lung Cancer <i>Tushar J. Desai</i> .....	351
Cancer Dependencies: PRMT5 and MAT2A in MTAP/p16-Deleted Cancers <i>Katya Marjon, Peter Kalev, and Kevin Marks</i> .....	371

## Errata

An online log of corrections to *Annual Review of Cancer Biology* articles may be found at <http://www.annualreviews.org/errata/cancerbio>